Harnessing cannabis chemistry to create validated medical treatments

Headquartered in Israel, OWC R&D is focused on discovering, developing and commercializing cannabis-based novel therapeutics products and treatments, specifically designed for several medical conditions and diseases.

Through close collaboration with some of Israel’s leading academic and medical centers, as well as pioneering researchers and scientists, OWC sponsors clinical studies that will provide patients with cannabis-based novel therapeutics products and treatments, and will improve the quality of their life.

learn More
Therapies for Skin Diseases

Whilst potentially suitable for multiple skin conditions, OWC’s topical ointment is being developed for Psoriasis as an initial indication. In pre-clinical trial studies our cannabinoid-based topical ointment demonstrated up to a 70 percent reduction in Psoriasis-related biomarkers, including keratinocyte proliferation and inflammatory cytokine expression.

OWC undertook a comprehensive pre-clinical study of cannabis-based topical ointment to determine its potential efficacy as a treatment for debilitating skin diseases. The pre-clinical study was performed at the Dead Sea Laboratory for Skin Biochemistry and Biotechnology in Ein Gedi, Israel.. The subsequent safety study was performed at a leading medical and academic facility in Israel.

learn More
Delivery System for Pain Management

OWCP has developed a cannabinoid-enriched sublingual disintegrating tablet to easily deliver medical cannabis. The tablet enables fast and effective absorption as the compounds are absorbed directly into the blood system through oral epithelial tissue.

The tablet is designed to treat various chronic pain syndromes and is intended to be a substitute for patients being treated with medical cannabis by smoking.

learn More
Multiple Myeloma

Multiple myeloma is a cancer of the plasma cells found in bone marrow and it constitutes 1 percent of total cancer incidence worldwide. The disease is responsible for 2 percent of total cancer-related deaths worldwide.

OWC has successfully tested a unique, innovative formulation aimed at Multiple Myeloma therapy.

Harnessing cannabis chemistry to create validated medical treatments

Headquartered in Israel, OWC R&D is focused on discovering, developing and commercializing cannabis-based novel therapeutics products and treatments, specifically designed for several medical conditions and diseases.

Through close collaboration with some of Israel’s leading academic and medical centers, as well as pioneering researchers and scientists, OWC sponsors clinical studies that will provide patients with cannabis-based novel therapeutics products and treatments, and will improve the quality of their life.

Therapies for Skin Diseases

Whilst potentially suitable for multiple skin conditions, OWC’s topical ointment is being developed for Psoriasis as an initial indication. In pre-clinical trial studies our cannabinoid-based topical ointment demonstrated up to a 70 percent reduction in Psoriasis-related biomarkers, including keratinocyte proliferation and inflammatory cytokine expression.

Delivery System for Pain Management

OWCP has developed a cannabinoid-enriched sublingual disintegrating tablet to easily deliver medical cannabis. The tablet enables fast and effective absorption as the compounds are absorbed directly into the blood system through oral epithelial tissue.

The tablet is designed to treat various chronic pain syndromes and is intended to be a substitute for patients being treated with medical cannabis by smoking.

Multiple Myeloma

Multiple myeloma is a cancer of the plasma cells found in bone marrow and it constitutes 1 percent of total cancer incidence worldwide. The disease is responsible for 2 percent of total cancer-related deaths worldwide.

OWC has successfully tested a unique, innovative formulation aimed at Multiple Myeloma therapy.

Close Menu